icotinib   

GtoPdb Ligand ID: 7641

Synonyms: BPI-2009H | Conmana®
icotinib is an approved drug
Compound class: Synthetic organic
Comment: Icotinib is a selective, orally available epidermal growth factor receptor tyrosine kinase inhibitor [1-3]. Icotinib is a 'pseudo' INN, that takes the form of an INN, but has not been submitted to the World Health Organisation for ratification.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 74.73
Molecular weight 391.15
XLogP 2.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES C#Cc1cccc(c1)Nc1ncnc2c1cc1OCCOCCOCCOc1c2
Isomeric SMILES C#Cc1cccc(c1)Nc1ncnc2c1cc1OCCOCCOCCOc1c2
InChI InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)
InChI Key QQLKULDARVNMAL-UHFFFAOYSA-N
References
1. Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, Wang F, Kang X, Tan F, Ding L et al.. (2012)
Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
Bioorg. Med. Chem. Lett., 22 (19): 6301-5. [PMID:22959248]
2. Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L, Hu Y, He W, Wang Y, Wang Y. (2012)
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
Lung Cancer, 76 (2): 177-82. [PMID:22112293]
3. Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y, Zhou J. (2011)
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Lung Cancer, 73 (2): 195-202. [PMID:21144613]